David A. Saperstein, MD is a practicing vitreoretinal surgeon with 20 years’ experience in clinical medicine and drug development. He has been an investigator in over 20 clinical trials in this field. He was an NIH funded clinician-scientist at Emory University and University of Washington and holds several patents and patents pending in pharmaceutical and surgical fields. He founded a successful biotech start-up that developed a family of retinoid drugs, now licensed to QLT Inc. (Vancouver). He is currently their Chief Medical Advisor. He also serves on the Scientific Advisory Board for AGTC, Inc. and was the Scientific Director of the Usher III Initiative.